INS and metabolic dysfunction-associated steatotic liver disease: In a randomized double-blind controlled trial (Amanat et al., 2018), compared with placebo, genistein supplementation (250 mg/day, 8 weeks) could reduce insulin levels and HOMA-IR in NAFLD patients.